RAPP
Rapport Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$25.93
+1.93%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 3.45x
- Price / sales
- 73.01x
- Price / cash flow
- -15.10x
Enterprise value
- Enterprise value
- $1.0B
- EV / sales
- 51.71x
- EV / EBITDA
- -6.97x
- EV / EBIT
- -6.74x
- Market cap
- $1.5B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026